2L A Stadtmauer, K Kariya, M Arslan, et al. Impact of a GnRH antag2onist (Ganirelix) on the outcome of controlled ovarian hyperstimula2tion(COH) in PCOS patients: a prospective and randomized study. Fertil Steril,2005,84( Supp 1)1 :S314.
3Ghazala Basir, Wai-sum O, Ernest Hung, et al. Morphometric a2nalysis of peri-imp lantation endometrium in patients having exces2 sively high oestradiol concentrations after ovarian stimulation. Hum Rep rod,2001,16 (3) :435-440.
4Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus WorkshopGroup Revised 2003 consensus on diagnostic criteria and long-termhealth risks related to polycystic ovary syndromel. Fertil Steril, 2004,81 : 19-25.
5Quezada S, Avellaira C, Johnson MC, et al. Evaluation of steroidrecep tors, coregulators, and molecules associated with uterine recep2tivity in secretory endometria from untreated women with polycystic o2vary syndrome. Fertil & Steril,2006,85 (4) :1017-1026.
6Hernandez E. Embryo imp lantation and GnRH antagonists:embryoimp lantation: the Rubicon for GnRH antagonists. Hum Rep rod, 2000,15(6) :1211-1216.
7Joao Sabino Canha-Filho Ph D, Nadiane LemosMD, Nina SteinMD, et al. Vascular endothelial growth factor and inhibin A in follicu2lar fluid of infertile patientswho underwent in vitro fertilization with agonadetrop in-releasing hormone antagonist. Fertility and Sterility, 2005,83 (4) :902-907.
1Ando H, Furugori K, Shibata D, et al. Dual rennin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series. Hum Reprod, 2002,18(6):1 219-22.
2Delbaere A, Bergmann PJ, Gervy-Decoster C, et al. Increased angiotensin n in ascites during severe ovarian hyperstimulation syndrome: role of early pregnancy and ovarian gonadotropin stimulation. Fertil Steril, 1997, 67(6):1 038-45.
3Delbaere A, Bergmann P J, Gervy-Decoster C, et al. Prorenin and active rennin concentrations in plasma and and ascites during severe ovarian hyperstimulations syndrome. Hum Reprod, 1997, 12(2):236-40.
4Delbaere A, Bergmann P J, Gervy-Decoster C, et al. Angiotensin Ⅱ immunoreactivity is elevated in ascites during severe ovarian hyperstimulation syndrome: implications for pathophysiology and clinical management. Fertil Steril, 1994,62(4):731-7.
5Levin ER, Rosen GF, Cassidenti DI,, et al. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest, 1998,102:1 978-85.
6D'Ambrogio G, Fasciani A, Monti M, et al. Serum vascular endothelial growth factor levels before starting gonadotropin treatment in women who have developed moderate forms of ovarian hyperstimulation syndrome. Gynecol Endocrinol,1999, Oct, 13(5):311-5.
7Ludwig M, Jelkmann W, Bauer O, et al. Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration. Hum Reprod, 1999,14(10):2 437-41.
8Enskog A, Nilsson L & Brannstrom M. Plasma levels of free vascular endothelial growth factor(165) (VEGF(165)) are not elevated during gonadotropin stimulation in m vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): results of a prospective cohort study with matched controls. Eur J Obstet Gynecol Reprod Biol,2001,96(2):196-201.
9Ekerhovd E, Enskog A, Caidahl K, et al. Plasma concentrations of nitrate during the menstrual cycle, ovarian stimulation and ovarian hyperstimulation syndrome. Hum Reprod, 2001, 16(7):1 334-9.
10Ito M, Harada T, Iwabe T, et al. Cytokine levels in a patient with severe ovarian hyperstimulation syndrome before and after the ultrafiltration and reinfusion of ascitic fluid. J Assist Reprod Genet, 2000, 17(2):118-20.
